Add-on lamotrigine treatment and plasma glutamate levels in epilepsy: Relation to treatment response

Epilepsy Research

Volumn 70, Issue 2-3, 2006, Pages 184-189

  Paraskevas, George P ^a   Triantafyllou, Nikolaos I ^a   Kapaki, Elisabeth ^a   Limpitaki, Georgia ^a   Petropoulou, Olga ^a   Vassilopoulos, Demetrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Epilepsy; Excitatory neurotransmitters; Glutamate; Lamotrigine

Indexed keywords

GLUTAMIC ACID; LAMOTRIGINE; VALPROIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; SEIZURE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; GLUTAMIC ACID; HUMANS; MALE; TIME FACTORS; TRIAZINES; VALPROIC ACID;

EID: 33746870823     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.05.004     Document Type: Article

References (24)

1. Araki K., Harada M., Ueda Y., Takino T., and Kuriyama K. Alteration of amino acid content of cerebrospinal fluid from patients with epilepsy. Acta Neurol. Scand. 78 (1988) 473-479
2. CCTILAE. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30 (1989) 389-399
3. Dagilas A., Kimiskidis V., Aggelopoulou M., Kapaki E., Fitili C., Libitaki G., Papagiannopoulos S., Kazis D., Kazis A., and Aidonis A. Changes in blood neurotransmitter and steroid levels during evoked vertigo. Otol. Neurootol. 26 (2005) 476-480
4. Darmaun D., Matthews D.E., and Bier D.M. Glutamine and glutamate kinetics in humans. Am. J. Physiol. (Endocrinol. Metab. 14) 251 (1986) E117-E126
5. Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., and Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41 (2000) 1364-1374
6. Deckers C.L., Hekster Y.A., Keyser A., Meinardi H., and Renier W.O. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 38 (1997) 570-575
7. Eriksson A.-S., and O'Connor W.T. Analysis of CSF amino acids in young patients with generalized refractory epilepsy during an add-on study with lamotrigine. Epilepsy Res. 34 (1999) 75-83
8. Hagenveldt I., and Arvidsson A. The distribution of amino acids between plasma and erythrocytes. Clin. Chim. Acta 100 (1980) 133-141
9. Kwan P., and Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 9 (2000) 464-468
10. Leach M.J., Marden C.M., and Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 27 (1986) 490-497
11. McGale E.H.F., Pye I.F., Stonier C., Hutchinson E.C., and Aber G.M. Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J. Neurochem. 29 (1977) 291-297
12. Meldrum B.S. The role of glutamate in epilepsy and other CNS disorders. Neurology 44 Suppl. 8 (1994) S14-S23
13. Munro H.N. Factors in the regulation of glutamate metabolism. In: Filer L.J., Garattini S., Kare M.R., Reynolds W.A., and Wurtman R.J. (Eds). Glutamic Acid: Advances in Biochemistry and Physiology (1979), Raven Press, New York 55-68
14. Niebroj-Dobosz I., Janik P., and Kwieciński H. Effect of riluzole on serum amino acids in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 106 (2002) 39-43
15. Pisani F., Otero G., Russo M.F., Di Perri R., Perucca E., and Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40 (1999) 1141-1146
16. Plaitakis A., and Caroscio J.T. Abnormal glutamate metabolism in ALS. Ann. Neurol. 18 (1985) 161
17. Plaitakis A., and Caroscio J.T. Abnormal glutamate metabolism in amyotophic lateral sclerosis. Ann. Neurol. 22 (1987) 575-579
18. Plaitakis A., Constantakakis E., and Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann. Neurol. 24 (1988) 446-449
19. Rainesalo S., Kernen T., Peltola J., and Saransaari P. Glutamate uptake in blood platelets from epileptic patients. Neurochem. Int. 43 (2003) 389-392
20. Rao M.L., Stefan H., Scheid C., Kuttler A.D.S., and Fröscher W. Serum amino acids, liver status and antiepileptic drug therapy in epilepsy. Epilepsia 34 (1993) 347-354
21. Rothstein J.D., Tsai G., Kuncl R.W., Clawson L., Cornblath D.R., Drachman D.B., Pestronk A., Stauch B.L., and Coyle J.T. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 28 (1990) 18-25
22. Ryberg H., Askmark H., and Persson L.I. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol. Scand. 108 (2003) 1-8
23. Stegink L.D., Filer L.J., Baker G.L., Mueller S.M., and Wu-Rideout M.Y.-C. Factors affecting plasma glutamate levels in normal adult subjects. In: Filer L.J., Garattini S., Kare M.R., Reynolds W.A., and Wurtman R.J. (Eds). Glutamic Acid: Advances in Biochemistry and Physiology (1979), Raven Press, New York 333-351
24. Wang S.J., Sihra T.S., and Gean P.W. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 12 (2001) 2255-2258